KR20230026490A - 아밀로이드 베타 1-42에 결합하는 항체를 이용한 축삭 손상의 예방 - Google Patents

아밀로이드 베타 1-42에 결합하는 항체를 이용한 축삭 손상의 예방 Download PDF

Info

Publication number
KR20230026490A
KR20230026490A KR1020237002535A KR20237002535A KR20230026490A KR 20230026490 A KR20230026490 A KR 20230026490A KR 1020237002535 A KR1020237002535 A KR 1020237002535A KR 20237002535 A KR20237002535 A KR 20237002535A KR 20230026490 A KR20230026490 A KR 20230026490A
Authority
KR
South Korea
Prior art keywords
patient
binding member
tau
antibody
nfl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237002535A
Other languages
English (en)
Korean (ko)
Inventor
키이스 탄
크레이그 셰링
존 알 심즈
제프리 엘 데이지
Original Assignee
메디뮨 리미티드
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메디뮨 리미티드, 일라이 릴리 앤드 캄파니 filed Critical 메디뮨 리미티드
Publication of KR20230026490A publication Critical patent/KR20230026490A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Radiation-Therapy Devices (AREA)
KR1020237002535A 2020-06-25 2021-06-25 아밀로이드 베타 1-42에 결합하는 항체를 이용한 축삭 손상의 예방 Pending KR20230026490A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063043872P 2020-06-25 2020-06-25
US63/043,872 2020-06-25
PCT/EP2021/067536 WO2021260193A1 (en) 2020-06-25 2021-06-25 Prevention of axonal damage using antibody binding to amyloid beta 1-42

Publications (1)

Publication Number Publication Date
KR20230026490A true KR20230026490A (ko) 2023-02-24

Family

ID=76662499

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237002535A Pending KR20230026490A (ko) 2020-06-25 2021-06-25 아밀로이드 베타 1-42에 결합하는 항체를 이용한 축삭 손상의 예방

Country Status (10)

Country Link
US (1) US20230287092A1 (enExample)
EP (1) EP4171742A1 (enExample)
JP (1) JP2023531069A (enExample)
KR (1) KR20230026490A (enExample)
CN (1) CN116547299A (enExample)
AU (1) AU2021295605A1 (enExample)
BR (1) BR112022026359A2 (enExample)
CA (1) CA3187785A1 (enExample)
IL (1) IL299215A (enExample)
WO (1) WO2021260193A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
WO2024015951A2 (en) * 2022-07-15 2024-01-18 Seq Biomarque, Llc Methods and materials for identifying biomarkers and/or pathways associated with alzheimer's disease
CN117624357B (zh) * 2024-01-26 2024-03-22 南京诺唯赞医疗科技有限公司 p-Tau 217特异性抗体及其在阿尔茨海默症辅助诊断试剂盒的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US151A (en) 1837-03-25 Spring-saddle
US5654A (en) 1848-06-27 Door-spring
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5503978A (en) 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
JP4531132B2 (ja) 1995-06-02 2010-08-25 ギリード・サイエンシズ・インコーポレーテッド 増殖因子に対する高親和性オリゴヌクレオチドリガンド
EP2198292A4 (en) * 2007-08-21 2010-09-08 Univ Washington IMPROVED MORBUS ALZHEIMER DIAGNOSIS
SMT202000340T1 (it) * 2012-10-15 2020-07-08 Medimmune Ltd Anticorpi contro il beta amiloide
CA2926092A1 (en) * 2013-10-24 2015-04-30 Nanosomix, Inc. Biomarkers and diagnostic methods for alzheimer's disease and other neurodegenerative disorders
RS64263B1 (sr) 2015-08-19 2023-07-31 Astrazeneca Ab Stabilna anti-ifnar1 formulacija
WO2017158064A1 (en) * 2016-03-15 2017-09-21 Astrazeneca Ab Combination of a bace inhibitor and an antibody or antigen-binding fragment for the treatment of a disorder associated with the accumulation of amyloid beta
WO2017193115A1 (en) * 2016-05-06 2017-11-09 Nanosomix, Inc. Synaptic protein biomarkers and differential diagnosis of alzheimer's disease and other neurodegenerative disorders
CA3032692A1 (en) * 2016-08-09 2018-02-15 Eli Lilly And Company Combination antibody therapy for the treatment of neurodegenerative diseases
CN110168375B (zh) * 2016-11-10 2022-09-16 脑生物标记解决方案哥德堡公司 检测个体罹患神经退行性疾病风险的方法
SG11202112329RA (en) * 2019-05-21 2021-12-30 Ac Immune Sa Anti-abeta vaccine therapy

Also Published As

Publication number Publication date
CA3187785A1 (en) 2021-12-30
IL299215A (en) 2023-02-01
EP4171742A1 (en) 2023-05-03
AU2021295605A1 (en) 2023-02-16
JP2023531069A (ja) 2023-07-20
TW202216188A (zh) 2022-05-01
US20230287092A1 (en) 2023-09-14
BR112022026359A2 (pt) 2023-01-17
CN116547299A (zh) 2023-08-04
WO2021260193A1 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
KR20230026490A (ko) 아밀로이드 베타 1-42에 결합하는 항체를 이용한 축삭 손상의 예방
CN113597431B (zh) 识别Tau的抗体
TWI730963B (zh) 抗-ｔａｕ抗體及使用方法
JP6290212B2 (ja) タウオパチーの処置方法
US11267877B2 (en) Anti-transthyretin antibodies
CN103380145B (zh) 人类抗-sod1抗体
CN110248959B (zh) 抗tau抗体和使用方法
CN107074937B (zh) 人源抗亨廷顿蛋白(htt)抗体及其用途
CN108064248B (zh) 人源抗二肽重复(dpr)抗体
US9309309B2 (en) Anti-ADDL monoclonal antibody and uses thereof
US9879076B2 (en) Methods and compositions with immune therapy for treatment of dementia
TW201821438A (zh) 抗-ｔａｕ抗體及使用方法
JP2020124203A (ja) 血液脳関門輸送分子およびそれらの使用
CA2974993A1 (en) Anti-transthyretin antibodies
US20140127225A1 (en) Compositions and methods for treating diseases of protein aggregation involving ic3b deposition
CN118765204A (zh) 抗trem2抗体的使用方法
JP2025185036A (ja) ソルチリンを認識する抗体
KR20250107906A (ko) 항-N3pGlu 아밀로이드 베타 항체, 그의 용량 및 용도
WO2015083125A2 (en) Antibodies that recognize iapp
EP4458860A1 (en) Antibody specifically binding to asm, and use thereof
TWI916375B (zh) 軸突損傷之預防
BR122025021109A2 (pt) Uso de um elemento de ligação que se liga seletivamente ao peptídeo beta amiloide 1-42 humano, método para avaliar a eficácia do uso, método para identificar um paciente como adequado para o uso, e kit
KR20220076658A (ko) Aimp2 및/또는 aimp2 응집체에 특이적으로 결합하는 항체
US20240009200A1 (en) Treatment of pulmonary arterial hypertension
JP2018508193A (ja) メディンを認識する抗体

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230120

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240625

Comment text: Request for Examination of Application